- Home
- YHC vs CANF Comparison
YHC vs CANF Comparison
Compare YHC & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YHC
- CANF
- Stock Information
- Founded
- YHC 2021
- CANF 1994
- Country
- YHC United States
- CANF Israel
- Employees
- YHC N/A
- CANF N/A
- Industry
- YHC Beverages (Production/Distribution)
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- YHC Consumer Staples
- CANF Health Care
- Exchange
- YHC Nasdaq
- CANF Nasdaq
- Market Cap
- YHC 12.3M
- CANF 14.4M
- IPO Year
- YHC N/A
- CANF N/A
- Fundamental
- Price
- YHC N/A
- CANF $1.48
- Analyst Decision
- YHC
- CANF Strong Buy
- Analyst Count
- YHC 0
- CANF 2
- Target Price
- YHC N/A
- CANF $14.00
- AVG Volume (30 Days)
- YHC 371.7K
- CANF 1.2M
- Earning Date
- YHC 04-02-2025
- CANF 12-31-2024
- Dividend Yield
- YHC N/A
- CANF N/A
- EPS Growth
- YHC N/A
- CANF N/A
- EPS
- YHC N/A
- CANF N/A
- Revenue
- YHC $2,272,001.00
- CANF $667,000.00
- Revenue This Year
- YHC N/A
- CANF $409.56
- Revenue Next Year
- YHC N/A
- CANF N/A
- P/E Ratio
- YHC N/A
- CANF N/A
- Revenue Growth
- YHC 158.05
- CANF N/A
- 52 Week Low
- YHC $0.40
- CANF $1.29
- 52 Week High
- YHC $3.47
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- YHC N/A
- CANF 35.58
- Support Level
- YHC N/A
- CANF $1.30
- Resistance Level
- YHC N/A
- CANF $1.72
- Average True Range (ATR)
- YHC 0.00
- CANF 0.18
- MACD
- YHC 0.00
- CANF -0.01
- Stochastic Oscillator
- YHC 0.00
- CANF 17.92
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).